CTLA4 and graft versus host disease: The anti-PD-1 + anti-CTLA-4 combination and MEDI8500 groups showed lower survival, and accelerated onset of clinical GvHD compared to vehicle and to the single agents anti-PD-1 and anti-CTLA-4, and generally higher GvHD lesion levels compared to the single agent treated mice.